Biotron Limited (ASX: BIT)
Health Care · Biotechnology · AU
AU$0.00
+25.00% today · -16.7% 1Y
Biotron Limited (ASX: BIT) operates in the Biotechnology industry within the Health Care sector. The company is valued at $4.81M and employs 4 people.
Over the last twelve months the share price has lost 16.7%, trading between 0.00 and 0.01.
Tweenvest scores Biotron Limited across four factors: quality 26/100, value 61/100. Its strongest factor is value.
BIT price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $4.81M
- Revenue (TTM)
- $-579.00
- P/E
- —
- EPS
- -0.00
- Dividend yield
- —
- Beta (5Y)
- -0.64
- 52-week high
- AU$0.01
- 52-week low
- AU$0.00
- Avg volume (3M)
- —
- Shares outstanding
- 2.70B
- Employees
- 4
- Next earnings
- —
About Biotron Limited
Biotron Limited is an Australian biotechnology firm dedicated to the creation and market introduction of small molecule therapies designed to combat a range of viral illnesses. Its flagship antiviral compound, BIT225, is currently undergoing Phase II clinical evaluations for addressing infections caused by SARS-CoV-2, HIV-1, and the hepatitis C virus. Established in 1999, the company operates from its main office in Sydney, Australia.
- ISIN
- AU000000BIT4
- Founded
- 1999
- Listed since
- Jan 23, 2001
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.